Yatsen achieves 36.8% revenue growth and non-GAAP profitability, driven by skincare brand success and strategic R&D initiatives.

OPERATOR - (00:01:34)

Ladies and gentlemen, good day and welcome to the Yatsen second quarter 2025 earnings conference call. Today's conference is being recorded at this time. I would like to turn the conference over to Irene Liu, Vice President, Head of Strategic Investment and Capital Markets. Please go ahead.

Irene Liu - Vice President, Head of Strategic Investment and Capital Markets - (00:01:59)

Thank you Operator Please note that discussion today will contain forward looking statements relating to the Company's future performance and are intended to qualify for the safe harbor from liability as established by the U.S. private securities litigation Reform Act. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions and other factors. Some of these risks are beyond the Company's control and could cause actual results to differ materially from those mentioned in today's press release and this discussion. A general discussion of the risk factors that could affect Yatsen Holding's business and financial results as included in certain filings of the Company with the securities and Exchange Commission. The Company does not undertake any obligation to update this forward looking information except as required by law. During today's call, management will also discuss certain non GAAP financial measures for comparison purposes only. Please see the earnings release issued earlier today for a definition of non GAAP financial measures and a reconciliation of GAAP to the non GAAP financial results. Joining us today on the call from Yatsen Holding's Senior Management are Mr. Zhengfong Huang, our founder, chairman and CEO, and Mr. Zhonghao Yang, our CFO and Director. Management will begin with prepared remarks and the call will conclude with the Q and A session. As a reminder, this conference is is being recorded. In addition, a webcast replay of this conference call will be available on Yatsen Holding's investor relations website at ir.yeltsinglobal.com I'll now turn the call over to Mr. Sun. Please go ahead. David.

David - (00:03:58)

Thank you Irene and thank you everyone for joining Yatsen Holding's second quarter 2025 earnings conference call today. I will begin with a brief macro overview and a summary of our financial results, followed by an update on how our R and D driven initiatives have supported the healthy development of our brand portfolio. China's beauty industry saw another modest quarter. According to the year adjusted data published by the National Bureau of Statistics, beauty sales increased by 2.6% year over year, falling short of the 5.4% growth in total retail sales of consumer goods, specifically during May and June, the key promotion period around the June 18 shopping festival. Beauty sales rose by 4.4% in May but declined by 2.3% in June. Despite the uncertain environment, we stayed focused on executing our R and D driven strategy. Anchored in our vision of becoming a world class pioneer in beauty innovation, we have continued expanding our international innovation network, attracting top global R and D talent and deepening collaborations across industries, academia and research institutions. These efforts have laid a solid foundation for both product innovation and brand equity which in turn supported the rebound in our financial performance. Building on the momentum that began in the fourth quarter of 2024, we delivered year over year revenue growth and achieved non GAAP profitability for the third consecutive quarter. In the second quarter of 2025, total net revenues grew by 36.8% year over year, significantly exceeding our previous guidance. Revenues from skin care brands increased 7.88.7% year over year, driven by an 88.1% growth in the combined revenue from our three major skincare brands, Galénic, Dr. Wu, Wu and Eiffelon. Our color cosmetics brand also delivers year over year growth of 8.8%. With Povideri brand back on a growth trajectory as operating leverage began to take effect, coupled with our efforts to improve efficiency in our operations and marketing spend, we narrowed our net loss margin to 1.8% from 10.8% for the prior year period and achieved a non GAAP net Profit margin of 1.1% for the second quarter of 2025 as compared with non GAAP net loss margin of 9.4% for the prior year period. Let me now walk you through some brand and product highlights. Powered by our solid R and D infrastructure, Galaniq posted strong results supported by a robust product of highlights and effective product marketing. Our number one VC Serum continued to lead sales while our upgraded Brightening Micromask featuring the brand's Micro Profusion and Active anchor technology ranked number one among premium single use masks on both Tmall and JD. During the June 18 period, the no. 2 VA Serum also received increasingly positive feedback, particularly on Douyin. In addition to online growth, we began expanding Galaniq's offline presence, opening Experience stores in Guangzhou, Shanghai, Wuhan and Shenzhen by the end of June. These stores are designed to strengthen brand visibility and deepen consumer engagement. Dr. Wu also benefits from a more diverse and balanced product portfolio. Its purifying Renewable Essence Toner, formulated with the Gentle Acid complex, effectively adjusts the antioxidant and brightening yield of oily and acne prone skin. This product resonates strongly with its targeted consumers and reinforced the brand positioning as a leader in professional skin renewal. The second quarter also marked a key milestone for Povideri since the launch of the Biolip essence lipstick. In September 2023, Povideri embraced a new philosophy of makeup gamification. Building on this, we introduced the third generation biotech technology and applied it to facial makeup. The new Bioface Essence foundation provides a flawless finish while supporting the skin barrier. We also launched the Translucent Blurring Setting Powder powered by the Smart Lock technology to control oil, combat oxidation and reduce dullness. These innovations played a key role in putting Pofidare back on its growth path. As our commitment to R and D remains essential to our long term strategy, we continue to strengthen our capabilities and presence in the scientific community. In May, we participated in the 2025 China Cosmetic science and Technology Conference in Yunnan as a guest speaker and joined a roundtable discussion on emotional skin care at the 2025 International Cosmetic Innovation Conference in Shanghai. In June, our joint laboratory with Regen Hospital unveiled its latest innovation at the 30th International Council of Nurse Congress in Health King, Finland. We are also proud of our ongoing social responsibility initiative. During the second quarter of 2025, our create a Beautiful Life program, launched in partnership with the China Women's Development foundation, celebrated the graduation of its first 2025 cohort in Guizhou. Now in its fifth year, the program provides free professional makeup training for low income women, helping them pursue new opportunities in employment and entrepreneurship. Meanwhile, Dr. Wu has entered the third year of his campus charity tour, promoting scientific skincare education and raising skin health awareness among university students across China. In summary, we are beginning to see tangible results from our long term focus on R and D. We remain committed to nursing our brands and delivering exceptional products to our customers. With that, I will now turn the call over to our CFO Dong Haoyang to discuss our financial performance. Thank you everyone.

Dong Haoyang - Chief Financial Officer - (00:11:39)

Thank you David and hello everyone. Before I get started, I would like to clarify that all financial numbers presented today are in renminbi amount and all percentage changes refer to year over year changes unless otherwise noted. Total net revenues for the second quarter of 2025 increased by 36.8% to 1.09 billion from 794.5 million for the prior year period. This increase was primarily due to a 78.7% year over year increase in net revenues from skincare brands combined with an 8.8% year over year increase in net revenues from color cosmetics brands. Gross profit for the second quarter of 2025 increased by 39.5% to 850 points from 609.4 million for the prior year period. Gross margin for the second quarter of 2025 increased to 78.3% from 76.7% for the prior year period. The increase was primarily driven by an increase in sales of higher gross margin products. Total operating expenses for the second quarter of 2025 increased by 21.7% to 905.9 million from 744.6 million for the prior year period. As a percentage of total net revenues, total operating expenses for the second quarter of 2025 was were 83.4% as compared with 93.7% for the prior year period. Fulfillment expenses for the second quarter of 2025 were 63.3 million as compared with 51.2 million for the prior year period. As a percentage of total net revenues, fulfillment expenses for the second quarter of 2025 decreased to 5.8% from 6.4% for the prior year period. The decrease was primarily due to further improvements in logistics efficiency, selling and marketing expenses for the second quarter of 2025 were 722.4 million as compared with 544.7 million for the prior year period. As a percentage of total net revenues, selling and marketing expenses for the second quarter of 2025 decreased to 66.5% from 68.6% for the prior year period. The decrease was primarily driven by the leveraging effect of higher total net revenue in the second quarter of 2025. General and administrative expenses for the second quarter of 2025 were 84.1 million as compared with $119.1 million for the prior year period. As a percentage of total net revenues, general and administrative expenses for the second quarter of 2025 decreased to 7.7% from 15% for the prior year period. The decrease was primarily driven by lower payroll expenses resulting from a reduction in general and administrative headcount coupled with the leveraging effect of higher total net revenues in the second quarter of 2025. Research and development expenses for the second quarter of 2025 were 36.1 million as compared with 29.7 million for the prior year period. As a percentage of total net revenues, research and development expenses for the second quarter of 2025 decreased to 3.3% from 3.7% for the prior year period. The decrease was primarily driven by by the leveraging effect of higher total net revenues in the second quarter of 2025. Loss from operations for the second quarter of 2025 was 55.5 million as compared with 135.2 million for the prior year period. Operating loss margin was 5.1% as compared with 17% for the prior year period. Non GAAP loss from operations for the second quarter of 2025 was $20.4 million as compared with $111.9 million for the prior year period. Non GAAP operating loss margin was 1.9% as compared with 14.1% for the prior year period. Net loss for the second quarter of 2025 was 19.5 million as compared with 85.5 million for the prior year period. Net Loss margin was 1.8% as compared with 10.8% for the prior year period. Net loss attributable to Yatsen Holding's ordinary shareholders for diluted ADAS for the second quarter of 2025 was 0.19 RMB as compared with 0.77 for the prior period. Non GAAP net income for the second quarter of 2025 was $11.5 million as compared with non GAAP net loss of $74.9 million for the prior year period. Non GAAP net income margin was 1.1% as compared with non GAAP net loss margin of 9.4% for the prior year period. Non GAAP net income attributable to Yassin's ordinary shareholders for diluted ads for the second quarter of 2025 was 0.13 RMB as compared with non GAAP net loss attributable to Yatsen Holding's ordinary shareholders for diluted ADS of 0.67 RMB for the prior year period. As of June 30, 2025, we had cash, restricted cash and short term investments of $1.35 billion as compared with $1.36 billion as of December 31, 2024. Net cash generated from operating activities for the second quarter of 2025 was 77.7 million as compared with net cash used in operating activities of 148.2 million for the prior year period. Looking at our business outlook for the third quarter of 2025, we expect our total net revenues to be between 778.6 million and 880.1 million, representing a year over year increase of approximately 15% to 30%. These forecasts reflect our current and preliminary view on the market and operational conditions which are subject to change. With that, I would now like to open the call to Q and A operator.

OPERATOR - (00:19:29)

Thank you and we will now begin the Question and Answer session. To ask a question, you may press Star then one on your touchtone phone. If you are using a speakerphone, please Pick up your handset before pressing the keys. And to withdraw your question, please press Star then two. For the benefit of all participants on today's call, if you wish to ask your question to management in Chinese, please immediately repeat your question in English. Our first question today will come from Maggie Huang of cicc. Please go ahead.

Maggie Huang - (00:20:11)

Well, thanks for taking my question. This is Maggie Huang from cicc. Firstly, congratulations for meeting our guidance and I have two questions. My first question is that as we enter into the second half of the year, how should we expect the trends of profitability for both skin care and color cosmetic categories? And how do we intend to strike a balance between promoting new product lines and improving our profitability? And my second question is about competition. So what's our view on the industry competition in Q3 and Q4, particularly the competition from foreign premium brands? That's my two questions. Thank you.

David - (00:21:00)

Okay, thank you very much for your question. Well, we've always been trying to strike a balance between our growth and profitability. And we don't believe that we have to sacrifice one for the other. And especially now, our high end skin care brands are growing even faster than our color cosmetics brands which tend to have higher gross margin and bottom line. So we're confident that as we grow our business both in skincare and color cosmetics going forward and especially skincare is showing a much stronger growth momentum. We believe that we can achieve both growth and profitability and competition. And I think you're right. Competition is going to be becoming more and more intense going forward, especially as our high end skincare brand is growing faster. We do expect that more competition from the international brands. But in order to drive our growth and strengthen our competing position, we are adopting a R and D driven growth strategy. So for the last four or five years, we've been one of the most aggressive players in the cosmetics industry to invest heavily in R and D. So now we build a very, I would say best in class R and D team and R and D infrastructure. If you look at our lab, our R and D center in Shanghai is one of the world class facilities. So that's how we view where to drive our future growth and especially to win the competition against, you know, other players in the industry.

Maggie Huang - (00:23:24)

Well, it's very clear. I have no more questions. Thank you very much.

OPERATOR - (00:23:32)

Again. To ask a question, please press star and then one. Our next question today will come from Lin Zhang of CITIC Securities. Please go ahead.

Lin Zhang - (00:23:48)

Thank you for taking my questions. I'm Lin Zhang from City securities and congratulations on the performance in the Second quarter, my first question is for their skincare brands. So I want to ask what are the key drivers behind the rapid growth of skin care brands, especially for the Galénic and Dr. Wu in the first half of the year and what is the outlook for the skincare business in the second half year and next year? And my second question is in which assets will the company make efforts to continuously improve the profitability? Thank you.

David - (00:24:29)

Thank you for the question.

Irene Liu - Vice President, Head of Strategic Investment and Capital Markets - (00:24:31)

So for the growth of our skincare brand. So we think there are a number of reasons. Primarily it's because of our continued investment into R and D and our gradual systematic upgrade of our R and D capabilities. As a result, we have a very strong pipeline of the new product innovations. So just to give you some examples, for example, for Galénic, for the past couple quarters we have introduced a series of new products including, you know, on top of, you know, very successful VC we introduced a VA serum. And also the Micromask series has been very successful. And we also widened the offering of the Micromask in terms of different efficacy. And we also upgraded the Micromask recently. And for Dr. Wu, the Renewal Essence Toner has been very successful. So we think mainly from the R and D upgrade and also the new product pipeline. And then in terms of outlook, we have provided the guidance for Q3 of 15 to 30% which really we think reflects our future outlook in terms of continued trend of our skincare brands in terms of the development. And then on your second question is our efforts to how to improve the profitability. We are continuing to optimizing our channel and product mix and at the same time streamline our operating expenses. But we think most of our brands, some of them given the high growth, we think there's still significant growth potential and those brands are right now remain well below their respective. That's why we continue plan to invest in the brand awareness and brand equity. So especially when there's new product launch. So as a result we think the profitability improvement will be gradual.

David - (00:26:40)

Okay, well just to add on to Irene's point, we do see clear opportunities to further improve profitability across several dimensions. First, we will continue to optimize our product mix by driving premiumization and hero products with stronger margins. Second, we're improving marketing efficiency through data driven CRM and better ROI discipline, shifting spending towards higher return channels. Thirdly, we are enhancing supply chain and operational efficiency to reduce costs and improve scale leverage. And lastly, as top line growth continues, we expect to gain operating leverage across fixed expenses. So altogether these initiatives give us confidence in steadily expanding profitability while maintaining growth.

Lin Zhang - (00:27:35)

Thank you. That's very clear. Thank you very much.

OPERATOR - (00:27:44)

This will conclude our question and answer session. I would like to turn the conference back over to management for any closing remarks.

UNKNOWN - (00:28:02)

Thank you again for joining us today. If you have any further questions, please feel free to contact us at Yatsen Holding directly. Our contact information for IR in both China and the US can be found in today's press release. Thank you, and have a great day.

OPERATOR - (00:28:20)

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.